Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chlamydia Infections | 20 | 2024 | 200 | 4.460 |
Why?
|
| Chlamydia | 10 | 2024 | 45 | 2.490 |
Why?
|
| Chlamydia muridarum | 5 | 2021 | 104 | 1.470 |
Why?
|
| Plasmodium falciparum | 9 | 2015 | 144 | 1.170 |
Why?
|
| Bacterial Vaccines | 8 | 2024 | 129 | 1.110 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2018 | 117 | 0.990 |
Why?
|
| Chlamydia trachomatis | 7 | 2024 | 70 | 0.970 |
Why?
|
| Merozoite Surface Protein 1 | 5 | 2010 | 34 | 0.960 |
Why?
|
| Receptors, KIR | 2 | 2018 | 5 | 0.930 |
Why?
|
| Dendritic Cells | 5 | 2021 | 132 | 0.870 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 201 | 0.850 |
Why?
|
| Vagina | 3 | 2023 | 89 | 0.810 |
Why?
|
| Pelvic Inflammatory Disease | 2 | 2020 | 19 | 0.780 |
Why?
|
| Genitalia | 2 | 2019 | 18 | 0.730 |
Why?
|
| Antibodies, Protozoan | 6 | 2010 | 82 | 0.720 |
Why?
|
| Malaria, Falciparum | 8 | 2015 | 90 | 0.670 |
Why?
|
| Mice | 22 | 2024 | 6644 | 0.630 |
Why?
|
| HIV Infections | 3 | 2023 | 2586 | 0.630 |
Why?
|
| Malaria | 2 | 2012 | 90 | 0.610 |
Why?
|
| Immunoglobulin G | 4 | 2024 | 259 | 0.570 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 236 | 0.560 |
Why?
|
| MicroRNAs | 4 | 2021 | 518 | 0.530 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2018 | 74 | 0.530 |
Why?
|
| Animals | 28 | 2024 | 16992 | 0.490 |
Why?
|
| Interleukin-10 | 2 | 2017 | 87 | 0.480 |
Why?
|
| Fertility | 1 | 2015 | 62 | 0.460 |
Why?
|
| Mice, Inbred C57BL | 11 | 2023 | 1869 | 0.450 |
Why?
|
| Female | 26 | 2024 | 24698 | 0.420 |
Why?
|
| Epitopes | 3 | 2024 | 157 | 0.400 |
Why?
|
| Carrier Proteins | 1 | 2015 | 321 | 0.400 |
Why?
|
| Antibody Specificity | 2 | 2010 | 76 | 0.370 |
Why?
|
| Antibodies, Blocking | 3 | 2010 | 11 | 0.360 |
Why?
|
| Antibodies, Bacterial | 5 | 2024 | 117 | 0.350 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 104 | 0.350 |
Why?
|
| Placenta | 1 | 2012 | 117 | 0.340 |
Why?
|
| Immunoglobulin M | 2 | 2010 | 86 | 0.330 |
Why?
|
| Pregnancy | 6 | 2023 | 1772 | 0.330 |
Why?
|
| Photoperiod | 2 | 2020 | 27 | 0.320 |
Why?
|
| Protozoan Proteins | 4 | 2012 | 191 | 0.300 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 1596 | 0.280 |
Why?
|
| Host-Pathogen Interactions | 3 | 2021 | 209 | 0.280 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2024 | 60 | 0.280 |
Why?
|
| Unfolded Protein Response | 2 | 2018 | 22 | 0.270 |
Why?
|
| Protein Subunits | 1 | 2005 | 93 | 0.230 |
Why?
|
| Humans | 19 | 2024 | 43102 | 0.220 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1070 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 201 | 0.220 |
Why?
|
| Vibrio cholerae | 4 | 2021 | 105 | 0.220 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2024 | 13 | 0.210 |
Why?
|
| Africa | 1 | 2023 | 82 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2015 | 96 | 0.200 |
Why?
|
| Uterus | 1 | 2023 | 52 | 0.200 |
Why?
|
| Antimalarials | 2 | 2015 | 64 | 0.200 |
Why?
|
| Child, Preschool | 6 | 2015 | 1546 | 0.200 |
Why?
|
| Infant | 5 | 2015 | 1175 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 2 | 2020 | 216 | 0.170 |
Why?
|
| Infant, Newborn | 3 | 2010 | 972 | 0.170 |
Why?
|
| Cell Line | 3 | 2020 | 1410 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 458 | 0.170 |
Why?
|
| Pregnancy, Ectopic | 1 | 2020 | 15 | 0.170 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2024 | 65 | 0.160 |
Why?
|
| Adoptive Transfer | 2 | 2021 | 53 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2020 | 2157 | 0.160 |
Why?
|
| Antigen Presentation | 3 | 2017 | 58 | 0.160 |
Why?
|
| Child | 7 | 2015 | 3443 | 0.160 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Immunity, Mucosal | 1 | 2019 | 53 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 704 | 0.140 |
Why?
|
| Biopsy | 1 | 2019 | 177 | 0.140 |
Why?
|
| Mice, Knockout | 3 | 2017 | 1035 | 0.140 |
Why?
|
| Vaccines, Subunit | 3 | 2024 | 34 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2021 | 561 | 0.130 |
Why?
|
| Genotype | 2 | 2018 | 800 | 0.130 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2017 | 33 | 0.130 |
Why?
|
| Haplotypes | 1 | 2018 | 197 | 0.130 |
Why?
|
| Adolescent | 7 | 2015 | 6081 | 0.130 |
Why?
|
| Fibrosis | 1 | 2017 | 169 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2020 | 434 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 934 | 0.120 |
Why?
|
| Computational Biology | 1 | 2019 | 327 | 0.120 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cross Protection | 1 | 2015 | 5 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 75 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 223 | 0.110 |
Why?
|
| Malaria Vaccines | 3 | 2010 | 21 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 561 | 0.100 |
Why?
|
| Nigeria | 3 | 2009 | 92 | 0.100 |
Why?
|
| Apoptosis | 3 | 2017 | 1568 | 0.100 |
Why?
|
| Caspase 1 | 1 | 2013 | 16 | 0.100 |
Why?
|
| Infertility, Female | 1 | 2013 | 24 | 0.100 |
Why?
|
| Calcium | 1 | 2015 | 491 | 0.090 |
Why?
|
| Sulfadoxine | 1 | 2012 | 6 | 0.090 |
Why?
|
| Pyrimethamine | 1 | 2012 | 10 | 0.090 |
Why?
|
| Mutation, Missense | 2 | 2012 | 91 | 0.090 |
Why?
|
| Adult | 5 | 2018 | 13872 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2013 | 227 | 0.090 |
Why?
|
| HIV-1 | 1 | 2018 | 755 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2012 | 104 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2010 | 3156 | 0.090 |
Why?
|
| Alleles | 1 | 2012 | 352 | 0.080 |
Why?
|
| Hela Cells | 3 | 2018 | 376 | 0.080 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 89 | 0.080 |
Why?
|
| Seasons | 2 | 2015 | 139 | 0.080 |
Why?
|
| Cytokines | 2 | 2017 | 678 | 0.080 |
Why?
|
| Young Adult | 3 | 2018 | 5080 | 0.080 |
Why?
|
| Inclusion Bodies | 2 | 2020 | 34 | 0.080 |
Why?
|
| Antigens, Protozoan | 1 | 2009 | 74 | 0.080 |
Why?
|
| Antibody Affinity | 1 | 2008 | 21 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2008 | 51 | 0.070 |
Why?
|
| Endemic Diseases | 1 | 2008 | 23 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 135 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2024 | 269 | 0.070 |
Why?
|
| Fibronectins | 2 | 2017 | 69 | 0.060 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 1 | 2006 | 8 | 0.060 |
Why?
|
| Cadherins | 2 | 2017 | 102 | 0.060 |
Why?
|
| Metalloproteases | 1 | 2006 | 18 | 0.060 |
Why?
|
| Male | 6 | 2015 | 23409 | 0.060 |
Why?
|
| Immunity, Innate | 2 | 2017 | 171 | 0.060 |
Why?
|
| Age Distribution | 1 | 2005 | 249 | 0.060 |
Why?
|
| Mice, Inbred CBA | 1 | 2024 | 42 | 0.060 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2006 | 82 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 224 | 0.050 |
Why?
|
| Cholera Toxin | 1 | 2024 | 41 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2017 | 462 | 0.050 |
Why?
|
| Ruminants | 1 | 2023 | 7 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 127 | 0.050 |
Why?
|
| Kenya | 2 | 2015 | 58 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2024 | 144 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2024 | 408 | 0.040 |
Why?
|
| Chromatography | 1 | 2001 | 17 | 0.040 |
Why?
|
| Immunologic Tests | 1 | 2001 | 11 | 0.040 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2019 | 5 | 0.040 |
Why?
|
| Porins | 1 | 2019 | 19 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2019 | 62 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 118 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 65 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2019 | 97 | 0.040 |
Why?
|
| Myosin Type II | 1 | 2018 | 17 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 355 | 0.040 |
Why?
|
| SOXF Transcription Factors | 1 | 2017 | 2 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 7 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 26 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 19 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 60 | 0.030 |
Why?
|
| Administration, Rectal | 1 | 2017 | 18 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 22 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 78 | 0.030 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2017 | 2 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2017 | 11 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 74 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2017 | 57 | 0.030 |
Why?
|
| Actins | 1 | 2017 | 164 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2017 | 25 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 181 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 139 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 712 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 25 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2015 | 23 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 148 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 95 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2015 | 50 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 436 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 2015 | 80 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 51 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 150 | 0.030 |
Why?
|
| Proteomics | 1 | 2017 | 378 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2017 | 536 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 595 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 117 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 384 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 945 | 0.030 |
Why?
|
| Mitochondria | 1 | 2017 | 523 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 1621 | 0.020 |
Why?
|
| Dihydropteroate Synthase | 1 | 2012 | 1 | 0.020 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2012 | 8 | 0.020 |
Why?
|
| DNA, Protozoan | 1 | 2012 | 26 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 386 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 104 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 455 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 735 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 515 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 2009 | 13 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 90 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 863 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 758 | 0.020 |
Why?
|
| Glycosylphosphatidylinositol Diacylglycerol-Lyase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 2006 | 5 | 0.020 |
Why?
|
| Life Cycle Stages | 1 | 2006 | 29 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1009 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1285 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 109 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2001 | 13 | 0.010 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2001 | 14 | 0.010 |
Why?
|
| Rural Health Services | 1 | 2001 | 48 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 611 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2001 | 1081 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 1857 | 0.010 |
Why?
|